alisol a profile

alisol A: has anti-hepatitis B virus activity; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	15558616
CHEMBL ID	467814
MeSH ID	M0040055

Synonym
(5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-17-[(1r,3s,4r)-3,4,5-trihydroxy-1,5-dimethyl-hexyl]-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-3-one
bdbm50130907
19885-10-0
alisol a
CHEMBL467814
dammar-13(17)-en-3-one, 11,23,24,25-tetrahydroxy-, (8alpha,9beta,11beta,14beta,23s,24r)-
S9277
CS-3647
AC-35101
alisol-a
HY-N0853
AKOS037514543
BS-15882
mfcd09953906
11,23,24,25-tetrahydroxydammar-13(17)-en-3-one
DTXSID10941738
Q63408699
CCG-269618
(5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-17-[(2r,4s,5r)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-3-one
alisola

Excerpt	Reference	Relevance
"Alisol A is a bioactive triterpenoid isolated from the Rhizoma Alismatis. "	( Alisol A Inhibited the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells by Inhibiting the Hippo Signaling Pathway. Chen, X; Liu, H, 2021)	3.51

Excerpt	Reference	Relevance
"Alisol A treatment can induce autophagy‑dependent apoptosis in human breast cancer cells via induction of ROS and DNA damage."	( Alisol A is potentially therapeutic in human breast cancer cells. Li, M; Shi, L; Shi, Y; Wang, H; Wang, M; Wang, P; Yu, J; Zhang, Q; Zhang, T; Zhao, H, 2020)	2.72

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cocaine esterase	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0058	2.4330	6.8000	AID1255832
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bile acid receptor	Homo sapiens (human)	EC50 (µMol)	10.1600	0.0040	1.4191	10.0000	AID1609537
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
prostaglandin metabolic process	Cocaine esterase	Homo sapiens (human)
xenobiotic metabolic process	Cocaine esterase	Homo sapiens (human)
catabolic process	Cocaine esterase	Homo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodeling	Bile acid receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Bile acid receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Bile acid receptor	Homo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoter	Bile acid receptor	Homo sapiens (human)
intracellular glucose homeostasis	Bile acid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Bile acid receptor	Homo sapiens (human)
transcription by RNA polymerase II	Bile acid receptor	Homo sapiens (human)
inflammatory response	Bile acid receptor	Homo sapiens (human)
cell-cell junction assembly	Bile acid receptor	Homo sapiens (human)
Notch signaling pathway	Bile acid receptor	Homo sapiens (human)
bile acid metabolic process	Bile acid receptor	Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathway	Bile acid receptor	Homo sapiens (human)
regulation of low-density lipoprotein particle clearance	Bile acid receptor	Homo sapiens (human)
intracellular receptor signaling pathway	Bile acid receptor	Homo sapiens (human)
negative regulation of type II interferon production	Bile acid receptor	Homo sapiens (human)
negative regulation of interleukin-1 production	Bile acid receptor	Homo sapiens (human)
negative regulation of interleukin-2 production	Bile acid receptor	Homo sapiens (human)
negative regulation of interleukin-6 production	Bile acid receptor	Homo sapiens (human)
negative regulation of tumor necrosis factor production	Bile acid receptor	Homo sapiens (human)
positive regulation of interleukin-17 production	Bile acid receptor	Homo sapiens (human)
toll-like receptor 9 signaling pathway	Bile acid receptor	Homo sapiens (human)
regulation of urea metabolic process	Bile acid receptor	Homo sapiens (human)
intracellular triglyceride homeostasis	Bile acid receptor	Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulus	Bile acid receptor	Homo sapiens (human)
bile acid signaling pathway	Bile acid receptor	Homo sapiens (human)
intracellular bile acid receptor signaling pathway	Bile acid receptor	Homo sapiens (human)
cholesterol homeostasis	Bile acid receptor	Homo sapiens (human)
defense response to bacterium	Bile acid receptor	Homo sapiens (human)
negative regulation of apoptotic process	Bile acid receptor	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Bile acid receptor	Homo sapiens (human)
innate immune response	Bile acid receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bile acid receptor	Homo sapiens (human)
positive regulation of insulin receptor signaling pathway	Bile acid receptor	Homo sapiens (human)
fatty acid homeostasis	Bile acid receptor	Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulus	Bile acid receptor	Homo sapiens (human)
regulation of bile acid biosynthetic process	Bile acid receptor	Homo sapiens (human)
cellular response to lipopolysaccharide	Bile acid receptor	Homo sapiens (human)
cellular response to fatty acid	Bile acid receptor	Homo sapiens (human)
cellular response to organonitrogen compound	Bile acid receptor	Homo sapiens (human)
negative regulation of monocyte chemotactic protein-1 production	Bile acid receptor	Homo sapiens (human)
regulation of cholesterol metabolic process	Bile acid receptor	Homo sapiens (human)
cellular response to bile acid	Bile acid receptor	Homo sapiens (human)
positive regulation of adipose tissue development	Bile acid receptor	Homo sapiens (human)
positive regulation of phosphatidic acid biosynthetic process	Bile acid receptor	Homo sapiens (human)
positive regulation of glutamate metabolic process	Bile acid receptor	Homo sapiens (human)
positive regulation of ammonia assimilation cycle	Bile acid receptor	Homo sapiens (human)
cell differentiation	Bile acid receptor	Homo sapiens (human)
negative regulation of inflammatory response	Bile acid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
methylumbelliferyl-acetate deacetylase activity	Cocaine esterase	Homo sapiens (human)
carboxylesterase activity	Cocaine esterase	Homo sapiens (human)
carboxylic ester hydrolase activity	Cocaine esterase	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Bile acid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Bile acid receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Bile acid receptor	Homo sapiens (human)
transcription coregulator binding	Bile acid receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Bile acid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Bile acid receptor	Homo sapiens (human)
nuclear receptor activity	Bile acid receptor	Homo sapiens (human)
protein binding	Bile acid receptor	Homo sapiens (human)
zinc ion binding	Bile acid receptor	Homo sapiens (human)
nuclear receptor binding	Bile acid receptor	Homo sapiens (human)
bile acid binding	Bile acid receptor	Homo sapiens (human)
bile acid receptor activity	Bile acid receptor	Homo sapiens (human)
sequence-specific DNA binding	Bile acid receptor	Homo sapiens (human)
nuclear retinoid X receptor binding	Bile acid receptor	Homo sapiens (human)
chenodeoxycholic acid binding	Bile acid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum	Cocaine esterase	Homo sapiens (human)
endoplasmic reticulum lumen	Cocaine esterase	Homo sapiens (human)
intracellular membrane-bounded organelle	Cocaine esterase	Homo sapiens (human)
nucleoplasm	Bile acid receptor	Homo sapiens (human)
chromatin	Bile acid receptor	Homo sapiens (human)
euchromatin	Bile acid receptor	Homo sapiens (human)
receptor complex	Bile acid receptor	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Bile acid receptor	Homo sapiens (human)
nucleus	Bile acid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay ID	Title	Year	Journal	Article
AID361554	Cytotoxicity against human HepG2.2.15 cells	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors.
AID1255833	Inhibition of human carboxylesterase 1 using 2-(2'-benzoyl-3'-methoxylphenyl)-benzothiazole as substrate at 0.1 to 200 uM by fluorescence assay	2015	Journal of natural products, Oct-23, Volume: 78, Issue:10	Protostane Triterpenoids from the Rhizome of Alisma orientale Exhibit Inhibitory Effects on Human Carboxylesterase 2.
AID361555	Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV e antigen secretion	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors.
AID361558	Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV surface antigen secretion	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors.
AID1609537	Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
AID1255832	Inhibition of human carboxylesterase 2 using 4-benzoyl-N-butyl-1,8-naphthalimide as substrate by fluorescence assay	2015	Journal of natural products, Oct-23, Volume: 78, Issue:10	Protostane Triterpenoids from the Rhizome of Alisma orientale Exhibit Inhibitory Effects on Human Carboxylesterase 2.
AID361556	Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV e antigen secretion	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors.
AID361557	Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV surface antigen secretion	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (4.17)	18.2507
2000's	5 (20.83)	29.6817
2010's	15 (62.50)	24.3611
2020's	3 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	24 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
bis(4-nitrophenyl)phosphate bis(4-nitrophenyl)phosphate: RN given refers to parent cpd	2.11	1	aryl phosphate
4-butyrolactone 4-Butyrolactone: One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.. tetrahydrofuranone : Any oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.. gamma-butyrolactone : A butan-4-olide that is tetrahydrofuran substituted by an oxo group at position 2.	2.11	1	butan-4-olide	metabolite; neurotoxin
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	2.21	1	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.11	1	D-glucopyranose	epitope; mouse metabolite
indole-3-carboxylic acid indole-3-carboxylic acid : An indole-3-carboxylic acid carrying a carboxy group at position 3.	2.05	1	indol-3-yl carboxylic acid	bacterial metabolite; human metabolite
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.04	1	oxygen hydride; oxygen radical; reactive oxygen species
alisol b alisol B: RN given for (8alpha,9beta,11beta,14beta,23S,24R)-isomer; isolated from Alismatis Rhizoma; structure in first source	3.6	8
ferulic acid ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.	2.11	1	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
sesquiterpenes [no description available]	2.97	4
ligustilide ligustilide: found in Umbelliferae plants; RN given refers to cpd without isomeric designation; structure in first source	2.11	1	butenolide	metabolite
alisol b monoacetate alisol B 23-acetate: from Alisma orientale rhizome; structure in first source	3.36	6	triterpenoid
alisol c 23-acetate alisol C 23-acetate: isolated from Alismatis Rhizoma; structure in first source	2.21	1
atractylenolide ii atractylenolide II: from Atractylodes ovata; structure in first source	2.11	1	sesquiterpene lactone
alisol b [no description available]	2.21	1	triterpenoid
alisol f [no description available]	2.98	4
alisol a 24-acetate alisol A 24-acetate: isolated from Alismatis Rhizoma; structure in first source	8.36	6
peoniflorin peoniflorin: from Radix and of Paeonia suffruticosa	2.11	1
alismol alismol: isolated from Alismatis Rhizoma; structure given in first source	2.42	2

Condition	Relationship Strength	Studies
Hepatitis B Virus Infection [description not available]	2.04	1
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	7.04	1
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	7.31	1
Cancer of Nasopharynx [description not available]	2.31	1
Invasiveness, Neoplasm [description not available]	2.66	2
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	2.31	1
Anterior Choroidal Artery Infarction [description not available]	2.6	1
Cerebral Ischemia [description not available]	7.6	1
Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).	2.6	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.6	1
Breast Cancer [description not available]	2.63	2
Breast Neoplasms Tumors or cancer of the human BREAST.	2.63	2
Benign Neoplasms [description not available]	2.17	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.17	1
Hyperlipemia [description not available]	2.17	1
Hyperlipidemias Conditions with excess LIPIDS in the blood.	2.17	1
Fatty Liver, Nonalcoholic [description not available]	2.21	1
Insulin Sensitivity [description not available]	2.21	1
Diseases, Metabolic [description not available]	2.21	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.21	1
Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)	2.21	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	7.21	1
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	2.21	1

alisol a

Description

Cross-References

Synonyms (20)

Research Excerpts

Overview

Treatment

Protein Targets (2)

Inhibition Measurements

Activation Measurements

Biological Processes (51)

Molecular Functions (18)

Ceullar Components (9)

Bioassays (8)

Research

Studies (24)

Market Indicators

Research Demand Index: 22.70

Study Types

alisol a

Description

Cross-References

Synonyms (20)

Research Excerpts

Overview

Treatment

Protein Targets (2)

Inhibition Measurements

Activation Measurements

Biological Processes (51)

Molecular Functions (18)

Ceullar Components (9)

Bioassays (8)

Research

Studies (24)

Market Indicators

Research Demand Index: 22.70

Study Types

Related Drugs (18)

Related Conditions (23)